Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372727 | 0.82 | ITK (0.63) | ITKLRRK2 | |
| SCHEMBL4903778 | 0.80 | MAP2K4 (0.51) | ITKTGFBR1MAPK14KDM4ENPC1 | |
| SCHEMBL2859279 | 0.78 | ITK (0.64) | ITKLRRK2KDM4EALDH1A1HPGD | |
| SCHEMBL2872558 | 0.76 | ITK (0.53) | ITKLRRK2 | |
| SCHEMBL2864569 | 0.76 | MAP2K4 (0.52) | ITKTGFBR1MAPK14NPC1MAPK1 | |
| SCHEMBL5382211 | 0.74 | LRRK2 (0.58) | ITKLRRK2 | |
| SCHEMBL1225637 | 0.74 | PDPK1 (0.67) | ITKTGFBR1 | |
| SCHEMBL27558623 | 0.74 | TTK (0.43) | TGFBR1MAPK14KDM4ENPC1ALDH1A1 | |
| SCHEMBL14539006 | 0.73 | ALOX5 (0.57) | ALOX5TGFBR1MAPK14 | |
| SCHEMBL31097132 | 0.73 | ALOX5 (0.57) | ALOX5TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| CN-1906189-A | 1-acetic acid-indole, -indazole and-benzimidazole derivatives for the treatment of respiratory diseases | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | IDO1, ABAT, ECI1 | ITK 3299/4885ALOX5 403/4885LRRK2 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.